Gamma-carbolines derivatives as promising agents for the development of pathogenic therapy for proteinopathy

Skvortsova, V.I., Bachurin, S.O., Ustyugov, A.A., Kukharsky, M.S., Deikin, A.V., Buchman, Vladimir L. ORCID: https://orcid.org/0000-0002-7631-8352 and Ninkina, Natalia ORCID: https://orcid.org/0000-0001-8570-5648 2018. Gamma-carbolines derivatives as promising agents for the development of pathogenic therapy for proteinopathy. Acta Naturae 10 (4) , pp. 59-62.

Preview

PDF - Published Version Available under License Creative Commons Attribution. Download (273kB) | Preview

Abstract

Uncontrolled protein aggregation, accompanied by the formation of specific inclusions, is a major component of the pathogenesis of many common neurodegenerative diseases known as proteinopathies. The intermediate products of this aggregation are toxic to neurons and may be lethal. The development strategy of pathogenic therapy for proteinopathy is based on the design of drugs capable of both inhibiting proteinopathy progression and increasing the survival of affected neurons. The results of a decade-long research effort at leading Russian and international laboratories have demonstrated that Dimebon (Latrepirdine), as well as a number of its derivatives from a gamma-carboline group, show a strong neuroprotective effect and can modulate the course of a neurodegenerative process in both in vitro and in vivo model systems. The accumulated data indicate that gamma-carbolines are promising compounds for the development of pathogenic therapy for proteinopathies.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Biosciences
Publisher:	RUSSIAN FEDERATION AGENCY SCIE
ISSN:	2075-8251
Date of First Compliant Deposit:	2 April 2019
Date of Acceptance:	21 September 2018
Last Modified:	05 May 2023 15:19
URI:	https://orca.cardiff.ac.uk/id/eprint/121324

Citation Data

Cited 7 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item